Guangzhou Yue Min Investment
VC Fund
Guangzhou Yue Min Investment is an investment firm
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Guangzhou Yue Min Investment invests in
Stages Guangzhou Yue Min Investment invests in
Countries Guangzhou Yue Min Investment invests in
Investment Focus
Industry
- Health Care 2 (67%)
- Biotechnology 2 (67%)
- Software 1 (33%)
- Medical Device 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Series C 1 (33%)
Country
- China 2 (67%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform. The company's independent intellectual property rights have solved the problems of drug drugability and toxic and side effects of antibody drugs. | Series A / Feb 09, 2022 | ||
| Iluvatar CoreX is a leading developer of high-performance computing solutions including System-on-a-Chip (SoC) chipset and its proprietary software platform. The company was founded in December 2015 by a group of world-class software and semiconductor experts from Silicon Valley and China which have been working together for more than two decadesin the field of AI at companies like Oracle, AMD/ATI and Fujitsu.Iluvatar has assembled a group of experts in system software, computing middleware, algorithms, parallel processing, GPU, AI, and IC design to develop end-to-end high-performance processing solutions in-house. Iluvatar solution addresses the limitations on computing power needs for AI applications by creatively exploiting the advantages of ultra-large-scale parallel computing architecture, with its general-purpose, standard, and high-performance cloud computing SoC solution (GP-GPU). Iluvatar solution is already proven. For the last 3 years, the company has been shipping its new generation of data processing software technology (soft silicon) named SkyDiscovery. | $185.6M / Series C / Mar 01, 2021 | ||
| Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including novel, humanizedmonoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. | $100M / Series B / Jan 08, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Guangzhou Yue Min Investment invest in?
Guangzhou Yue Min Investment invests primarily in Health Care, Biotechnology and Software startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Guangzhou Yue Min Investment last invest?
The most recent investment recorded for Guangzhou Yue Min Investment closed in Feb 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
